Rameda Pharma has acquired a generic anti-inflammatory molecule, according to a statement (pdf). The unnamed molecule, which relieves pain associated with rheumatoid arthritis, psoriatic arthritis, osteoarthritis and other chronic ailments, would have been among Rameda’s top-10 selling products had it been in its lineup in 2019. An independent market research firm suggested the molecule generated revenues of EGP 71 mn last year based on its retail price. “With this agreement, Rameda gains access to a new, fast-growing therapeutic area that has displayed a 5-year CAGR of c.41% between 2015 and 2019,” the company said.

Background: Rameda had flagged the acquisition of new molecules as being high on its priority list for the use of proceeds from its 2019 IPO.

Tags: